China Cancer drug development has produced an abundance of therapies, yet outcomes in solid tumours remain constrained by resistance and relapse. In this interview, Zaiqi Wang, Chairman and CEO of InxMed, explains why the company starts from tumour defence biology rather than individual targets, and how this perspective informs its combination…
China Shaped by decades across US biotech, big pharma, and China’s high-intensity innovation environment, Dr Jing Li brings a rare end-to-end perspective on how biologics move from idea to impact. In this interview, he explains why VelaVigo is built around first-in-class biology, disciplined execution, and global partnering, and how those choices…
See our Cookie Privacy Policy Here
